(VIANEWS) – Shares of Viking Therapeutics (NASDAQ: VKTX) rose 9.83% to $10.50 at 11:45 EST on Thursday, after two consecutive sessions in a row of losses. NASDAQ is jumping 0.46% to $11,965.50, following the last session’s downward trend. This seems, as yet, a somewhat bullish trend exchanging session today.
Viking Therapeutics’s last close was $9.56, 0.62% under its 52-week high of $9.62.
About Viking Therapeutics
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, Viking Therapeutics has a trailing twelve months EPS of $-0.6.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -33.84%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is a negative 50% and a negative 14.3%, respectively.
Volatility
Viking Therapeutics’s last week, last month’s, and last quarter’s current intraday variation average was 1.79%, 0.37%, and 4.34%.
Viking Therapeutics’s highest amplitude of average volatility was 2.62% (last week), 2.76% (last month), and 4.34% (last quarter).
More news about Viking Therapeutics (VKTX).
